Severine Vermeire

Summary

Affiliation: University Hospitals Leuven
Country: Belgium

Publications

  1. doi request reprint Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium Electronic address
    Lancet . 2016
  2. ncbi request reprint Long-term Efficacy of Vedolizumab for Crohn's Disease
    Severine Vermeire
    University Hospitals Leuven, Belgium
    J Crohns Colitis . 2016
  3. ncbi request reprint Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
    Erwin Dreesen
    Department of Clinical and Experimental Medicine, Faculty of Medicine, University of Leuven, P O Box 7003, 3000 Leuven, Belgium
    Curr Drug Targets . 2016
  4. pmc Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease
    Severine Vermeire
    KU Leuven, Translational Research Center for Gastrointestinal Disorders TARGID, University Hospitals Leuven, Leuven, Belgium
    J Crohns Colitis 10:387-94. 2016
  5. doi request reprint Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
    Severine Vermeire
    University of Leuven, Leuven, Belgium Electronic address
    Lancet 384:309-18. 2014
  6. doi request reprint Management of inflammatory bowel disease in pregnancy
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    J Crohns Colitis 6:811-23. 2012
  7. doi request reprint Classification of inflammatory bowel disease: the old and the new
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 28:321-6. 2012
  8. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
  9. doi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
  10. doi request reprint Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:748-61. 2011

Detail Information

Publications95

  1. doi request reprint Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium Electronic address
    Lancet . 2016
    ..Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease...
  2. ncbi request reprint Long-term Efficacy of Vedolizumab for Crohn's Disease
    Severine Vermeire
    University Hospitals Leuven, Belgium
    J Crohns Colitis . 2016
    ..The GEMINI long-term safety [LTS] trial is an ongoing open-label study investigating the safety of vedolizumab. We present interim exploratory analyses of efficacy in patients with Crohn's disease...
  3. ncbi request reprint Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
    Erwin Dreesen
    Department of Clinical and Experimental Medicine, Faculty of Medicine, University of Leuven, P O Box 7003, 3000 Leuven, Belgium
    Curr Drug Targets . 2016
    ..This review provides a clinician-oriented overview of the state-of-the-art, the gaps in current knowledge and future potential of indi¬vidualized predictive treatment...
  4. pmc Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease
    Severine Vermeire
    KU Leuven, Translational Research Center for Gastrointestinal Disorders TARGID, University Hospitals Leuven, Leuven, Belgium
    J Crohns Colitis 10:387-94. 2016
    ..We assessed the impact of faecal microbiota transplantation in patients with inflammatory bowel disease and studied predictors of clinical (non-)response in microbial profiles of donors and patients...
  5. doi request reprint Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
    Severine Vermeire
    University of Leuven, Leuven, Belgium Electronic address
    Lancet 384:309-18. 2014
    ..Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis...
  6. doi request reprint Management of inflammatory bowel disease in pregnancy
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    J Crohns Colitis 6:811-23. 2012
    ..This article aims to provide a framework for clinical decision making in IBD based on review of the literature on pregnancy-related topics...
  7. doi request reprint Classification of inflammatory bowel disease: the old and the new
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 28:321-6. 2012
    ..Basic scientists on the other hand prefer classifications that would allow to better understand the pathophysiology of the different manifestations of Crohn's disease and ulcerative colitis...
  8. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
    ..Unequivocal histologic markers predicting recurrence have not been identified. We assessed the predictive value of neural lesions for early endoscopic CD recurrence and long-term reintervention risk...
  9. doi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
    ..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
  10. doi request reprint Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:748-61. 2011
    ..This migration is regulated by cell adhesion molecules (CAMs), and selective antimigration therapies have been developed. This study investigated the effect of infliximab therapy on the mucosal gene expression of CAMs in IBD...
  11. doi request reprint Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease
    Mirjam Bueno de Mesquita
    Department of Paediatric Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Eur J Pediatr 168:575-83. 2009
    ..6%, respectively, p<0.0001) and more often had concomitant immune-mediated diseases and a trend for more seroreactivity towards ASCA...
  12. pmc Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1536-42. 2007
    ....
  13. pmc Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease
    Christine Breynaert
    Translational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    PLoS ONE 8:e68876. 2013
    ..The aim of this study was to investigate changes in connective tissue in a chronic murine model resulting from repeated cycles of dextran sodium sulphate (DSS) ingestion, to mimic the relapsing nature of the human disease...
  14. ncbi request reprint Pancreatic autoantibodies in inflammatory bowel disease
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Inflamm Bowel Dis 10:771-7. 2004
    ..We studied PABs in patients with inflammatory bowel disease (IBD), unaffected family members, and control subjects...
  15. doi request reprint Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients
    Marko Brinar
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    J Crohns Colitis 6:43-50. 2012
    ..Genetic variants in autophagy genes IRGM and ATG16L1 have been associated with susceptibility to Crohn's disease. We therefore investigated whether variants in autophagy genes contribute to granuloma formation...
  16. doi request reprint Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls
    Talat Bessissow
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium Department of Gastroenterology, Royal Victoria Hospital, McGill University Health Center, Montreal, Canada Electronic address
    J Crohns Colitis 7:e580-7. 2013
    ..Pain and nausea are often reported during bowel cleansing (BC) for ileocolonoscopy (IC). We aimed to explore putative mechanisms associated with impaired tolerance to BC...
  17. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  18. pmc Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    PLoS ONE 4:e7984. 2009
    ..We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD...
  19. doi request reprint Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    J Hepatol 50:150-7. 2009
    ..The histological features in the liver of PSC patients are similar to those observed in cystic fibrosis (CF). Our aim was to study whether variants in the CFTR gene are associated with the occurrence and/or evolution of PSC...
  20. ncbi request reprint Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases
    Marie Pierik
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:1-8. 2006
    ..This is underscored by the finding of the association between CARD15 variants and Crohn's disease (CD) and D299G in Toll-like receptor (TLR) 4 and IBD. Our aims were to study nonsynonymous polymorphisms in other TLR genes in IBD...
  21. doi request reprint Identifying predictors of low adherence in patients with inflammatory bowel disease
    Sofie Coenen
    aDepartment of Gastroenterology, University Hospitals Leuven bTranslational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven cMACX, Integrated Care, Aartselaar, Belgium
    Eur J Gastroenterol Hepatol 28:503-7. 2016
    ..Low adherence to therapy leads to poorer disease outcome. Therefore, we aimed to identify predictors of low adherence in the Belgian IBD population...
  22. doi request reprint Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
    Konstantinos Papamichael
    KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders TARGID, and University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
    Clin Gastroenterol Hepatol 14:543-9. 2016
    ..We investigated whether infliximab concentrations during induction therapy are associated with short-term mucosal healing (STMH) in patients with UC...
  23. ncbi request reprint Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 97:2357-63. 2002
    ..The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab...
  24. doi request reprint Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing
    Talat Bessissow
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 107:1684-92. 2012
    ..We aimed to investigate the predictive role of serologic and histologic markers on disease relapse in UC patients with endoscopically inactive disease...
  25. ncbi request reprint The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:870-8. 2006
    ..Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms...
  26. doi request reprint Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease
    Matthias Jürgens
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 9:421-7.e1. 2011
    ..C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab...
  27. doi request reprint Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:2090-8. 2010
    ..However, a subset of patients shows incomplete or no response to this agent. In this study we investigated whether we could identify a mucosal gene panel to predict (non)response to IFX in CD...
  28. doi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010
    ..In case reports, thiopurine analogs and infliximab (IFX) have been proposed as effective therapy in this setting. We analyzed the long-term efficacy of IFX in Belgian patients with refractory pouch complications...
  29. doi request reprint Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 15:1295-301. 2009
    ..Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated...
  30. pmc Treatment of severe steroid refractory ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
    World J Gastroenterol 14:5508-11. 2008
    ..Therefore, patients not responding to these agents within 5-7 d should be considered for colectomy and responders should be closely monitored for infections...
  31. ncbi request reprint Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 129:1845-53. 2005
    ..We studied mutation prevalence, assessed phenotypic expression, and performed conditional analysis to examine evidence for gene-gene interactions...
  32. doi request reprint Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis
    Bart Lemmens
    Translational Cell and Tissue Research, Department of Imaging and Pathology, University Hospital KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 19:1194-201. 2013
    ..It is still unknown how well they correlate and whether scoring both endoscopy and histology better reflects the true disease activity than each of the methods separately...
  33. ncbi request reprint Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease
    Nele Esters
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 99:299-305. 2004
    ..Since nothing is known about the transmission of these variants within families, this was the subject of our study in Flemish patients with inflammatory bowel disease (IBD) and their healthy relatives...
  34. doi request reprint Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis
    Vicky De Preter
    Translational Research Center for Gastrointestinal Disorders TARGID and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
    Inflamm Bowel Dis 18:2371-80. 2012
    ..In this study we measured colonic mucosal TST enzyme activity and gene expression in UC and controls. In addition, the influence of sulfides on butyrate oxidation was evaluated...
  35. doi request reprint Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 17:1846-54. 2011
    ..Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy...
  36. ncbi request reprint C-reactive protein as a marker for inflammatory bowel disease
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:661-5. 2004
    ..However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate...
  37. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
    ..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
  38. doi request reprint Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
    Konstantinos Karmiris
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 137:1628-40. 2009
    ....
  39. pmc New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gut 56:1394-403. 2007
    ....
  40. doi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..More than 80% of Crohn's disease (CD) patients undergoing resection suffer recurrence of their disease. Therapy with aminosalicylates, antimetabolites, or antibiotics leads to a modest reduction in the incidence of recurrence...
  41. doi request reprint Genetic risk profiling and prediction of disease course in Crohn's disease patients
    Liesbet Henckaerts
    Department of Medicine, Gastroenterology Section, Catholic University of Leuven, Leuven, Belgium
    Clin Gastroenterol Hepatol 7:972-980.e2. 2009
    ..We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated...
  42. doi request reprint Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease
    Marie Joossens
    Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:58-67. 2010
    ..Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk...
  43. ncbi request reprint Mucosal healing and anti TNFs in IBD
    Gert Van Assche
    Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium
    Curr Drug Targets 11:227-33. 2010
    ..In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered...
  44. ncbi request reprint The value of serologic markers in indeterminate colitis: a prospective follow-up study
    Sofie Joossens
    Gastroenterology Unit, Department of Pathology, U Z Gasthuisberg, Leuven, Belgium
    Gastroenterology 122:1242-7. 2002
    ..We evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC...
  45. doi request reprint Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
    Zhe Li
    Laboratory of Experimental Immunology, Catholic University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 16:1299-310. 2010
    ..Therefore, we investigated the effect of infliximab (IFX) therapy on Forkhead box protein3 (Foxp3) T cells in blood and intestinal mucosa from Crohn's disease (CD) and ulcerative colitis (UC)...
  46. doi request reprint Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 25:323-8. 2009
    ..To focus on the emerging clinical evidence for the use of traditional immunosuppressives and biologicals in the treatment of inflammatory bowel disease...
  47. doi request reprint Seroreactivity against glycolytic enzymes in inflammatory bowel disease
    Nathalie Vermeulen
    Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
    Inflamm Bowel Dis 17:557-64. 2011
    ..Patients with inflammatory bowel disease (IBD) carry autoantibodies such as perinuclear antineutrophil cytoplasmic antibodies. The aim of the current study was to further characterize the immune reactivity in IBD...
  48. doi request reprint Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project
    Isabelle Cleynen
    Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    Gut 62:1556-65. 2013
    ..We aimed to investigate the influence of CD-SNPs and basic patient characteristics on CD clinical course, and develop statistical models to predict CD clinical course...
  49. pmc Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab
    Clémentine Perrier
    Department of Gastroenterology, Translational Research Centre for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium
    Immunology 138:47-56. 2013
    ..Expression is localized in B cells, suggesting that IL-15 regulates B-cell functions during bowel inflammation. No change in release of sIL-15Rα is observed in patients treated with IFX...
  50. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
    ..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
  51. doi request reprint Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease
    Wim Janssens
    Department of Human Genetics, Katholieke Universiteit Leuven, Gasthuisberg O and N1 602, Herestraat 49, B 3000, Leuven, Belgium
    Am J Respir Crit Care Med 182:163-9. 2010
    ..Controversy still exists on whether the beta-defensins genes determine susceptibility for chronic obstructive pulmonary disease (COPD)...
  52. doi request reprint Serum sickness, encephalitis and other complications of anti-cytokine therapy
    Severine Vermeire
    University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:101-12. 2009
    ..We discuss the safety aspects of the biological agents in this chapter and, where available, give ways to prevent and/or treat them...
  53. doi request reprint Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study
    Christine Breynaert
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Am J Gastroenterol 106:778-85. 2011
    ..The primary end point was the incidence of infusion reactions in both groups...
  54. doi request reprint Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives
    Marie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 60:631-7. 2011
    ..Whether dysbiosis is present in relatives of patients CD was also examined...
  55. ncbi request reprint Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
    Tibor Hlavaty
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:372-9. 2007
    ..Predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. We aimed to develop a predictive model for the response to infliximab in CD...
  56. doi request reprint Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC
    Ingrid Arijs
    Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
    Gut . 2016
    ..There are no data on histological healing with VDZ. We studied histological changes following VDZ therapy and compared gene expression in patients with UC before and after therapy...
  57. doi request reprint Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases
    Zhe Li
    Clinical Immunology Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Division of Gastroenterology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Department of Bioinformatics Statistical Genetics, Université of Liège, Liege, Belgium and Experimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 21:2787-96. 2015
    ..In this study we investigated peripheral blood B cells, B-cell subsets, and CD40 expression in patients with IBD before and during anti-TNF therapy with infliximab (IFX)...
  58. pmc Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis
    Jan Van der Goten
    Translational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium Gene Expression Unit, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
    PLoS ONE 9:e116117. 2014
    ..Integration of mRNA and miRNA expression profiling may allow the identification of functional links between dysregulated miRNAs and their target mRNA...
  59. ncbi request reprint Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis
    David N Moskovitz
    Department of Internal Medicine, University Hospital, Gasthuisberg Herestraat, Leuven, Belgium
    Clin Gastroenterol Hepatol 4:760-5. 2006
    ..Cyclosporine (CSA) has been shown to be effective in steroid-refractory ulcerative colitis (UC) and as an alternative to glucocorticosteroids in patients with severe attacks of UC. Our aim was to investigate the long-term efficacy of CSA...
  60. doi request reprint Targeting TNF-α for the treatment of inflammatory bowel disease
    Thomas Billiet
    University of Leuven, University Hospitals Gasthuisberg, KU Leuven, Department of Gastroenterology, Herestraat 49, O and N1, Box 701, 3000 Leuven, Belgium 3216330277 3216330723
    Expert Opin Biol Ther 14:75-101. 2014
    ..Both in short- and long-term, anti-TNF therapy has been shown to reduce symptoms, heal mucosal ulcers, reduce hospitalizations and surgeries and spare corticosteroids...
  61. ncbi request reprint Protein-losing enteropathy in Crohn's disease
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Acta Gastroenterol Belg 69:384-9. 2006
    ..Histology showed severe mesenteric granulomatosis, dilated lymph vessels and granulomatous vasculitis. After the resection our patient improved without further albumin infusions and the oedema resolved...
  62. ncbi request reprint Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    N Engl J Med 353:362-8. 2005
    ..There was staining of the brain lesion for polyomavirus. This case report, along with two others, suggests that anti-alpha4-integrin therapy can result in JC virus-induced PML...
  63. doi request reprint Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway
    Vicky De Preter
    Translational Research Center for Gastrointestinal Disorders TARGID and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Gasthuisberg, K U Leuven, Leuven, Belgium
    Inflamm Bowel Dis 18:1127-36. 2012
    ..In the present study we correlated butyrate uptake and oxidation to the gene expression of the butyrate transporter SLC16A1 and the enzymes involved in butyrate oxidation (ACSM3, ACADS, ECHS1, HSD17B10, and ACAT2) in UC and controls...
  64. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003
    ..We evaluated the clinical significance of these antibodies in patients with Crohn's disease...
  65. ncbi request reprint Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 14:20-8. 2008
    ..During the course of their disease, about 30% of patients with ulcerative colitis (UC) will undergo proctocolectomy with ileal pouch-anal anastomosis (IPAA). We evaluated the outcome of IPAA in a Belgian referral center...
  66. ncbi request reprint Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Curr Gastroenterol Rep 11:504-8. 2009
    ..Finally, it remains unclear if and when a biologic agent can be stopped in patients with long-standing remission...
  67. ncbi request reprint Long-term outcome after infliximab for refractory ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Crohns Colitis 2:219-25. 2008
    ..We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified...
  68. ncbi request reprint Predictors of early response to infliximab in patients with ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:123-8. 2007
    ..Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response...
  69. ncbi request reprint Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease
    Tibor Hlavaty
    University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:199-204. 2006
    ..Whereas the validity and reproducibility of the IBDQ have been extensively studied, there are limited data on its short-term responsiveness and cutoff values for remission and partial clinical response...
  70. doi request reprint Recent advances: Personalised use of current Crohn's disease therapeutic options
    Severine Vermeire
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium
    Gut 62:1511-5. 2013
    ..What is needed now are pharmaco-economic studies showing that personalised management of CD is cost effective. ..
  71. doi request reprint Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis
    Clémentine Perrier
    Department of Gastroenterology, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 19:246-53. 2013
    ..The aim of this study was to determine whether neutralization of sTNF exclusively, by the use of a dominant negative mutant of TNF (XENP1595), could reduce the severity of colitis in mice...
  72. ncbi request reprint Immunogenicity of infliximab: how to handle the problem?
    Filip Baert
    Department of Gastroenterology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Acta Gastroenterol Belg 70:163-70. 2007
    ..Antibody formation is associated with allergic reactions and loss of response...
  73. ncbi request reprint Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study
    Severine Vermeire
    Gastroenterology Department, University Hospital Gasthiuisberg, Leuven, Belgium
    Gastroenterology 125:32-9. 2003
    ..We investigated the occurrence of antinuclear antibodies in 125 consecutive Crohn's disease patients and studied the relationship with symptoms of autoimmunity...
  74. pmc Pharmacogenetics in inflammatory bowel disease
    Marie Pierik
    Department of Gastro enterology, University of Hospital Gasthuisberg, Leuven, Belgium
    World J Gastroenterol 12:3657-67. 2006
    ..An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies...
  75. pmc Molecular reclassification of Crohn's disease by cluster analysis of genetic variants
    Isabelle Cleynen
    Department of Gastroenterology, KU Leuven, Leuven, Belgium
    PLoS ONE 5:e12952. 2010
    ..We hypothesized that the large number of confirmed genetic variants enables (better) classification of CD patients...
  76. doi request reprint Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study
    Johan Fevery
    Department of Hepatology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Liver Int 32:214-22. 2012
    ..The outcome of primary sclerosing cholangitis (PSC) has improved by liver transplantation (LT), but patients often develop malignancies. We analysed morbidity and mortality patterns to define strategies to prevent complications...
  77. ncbi request reprint Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
    J Crohns Colitis 2:142-51. 2008
    ..We investigated the role of antimicrobial and antiglycan antibodies and polymorphisms in microbial pattern recognition receptor genes...
  78. doi request reprint Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
    Inflamm Bowel Dis 17:1392-7. 2011
    ..Our aim was to investigate polymorphisms in selected autophagy genes for their association with susceptibility to CD...
  79. doi request reprint Identification of a novel autoantigen in inflammatory bowel disease by protein microarray
    Nathalie Vermeulen
    Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
    Inflamm Bowel Dis 17:1291-300. 2011
    ..Patients with inflammatory bowel disease (IBD) display immunoreactivity to self-antigens and microbial antigens. We used a protein microarray approach to identify novel autoantigens in IBD...
  80. doi request reprint Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    Geert D'Haens
    Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 18:2218-24. 2012
    ..Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity...
  81. ncbi request reprint Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
    Clin Chem 50:1422-5. 2004
  82. doi request reprint Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging
    Konstantinos Karmiris
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 9:130-6. 2011
    ..Magnetic resonance imaging (MRI) is used to assess the outcome of infliximab (IFX) therapy in patients with perianal fistulizing Crohn's disease (pfCD). However, few long-term data are available about its efficacy...
  83. doi request reprint Management of acute severe ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gut 60:130-3. 2011
    ..Whereas prolonged exposure to steroids predisposes to an increased rate of peri-operative complications it is still debated whether cyclosporine or infliximab increase peri-operative morbidity in ulcerative colitis...
  84. ncbi request reprint Medical treatment of inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 21:443-7. 2005
    ..Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field...
  85. pmc Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Paul Rutgeerts
    University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
    Gut 56:453-5. 2007
    ..We propose that future studies should focus on healing and disease course as primary outcome measures...
  86. ncbi request reprint Safety issues with biological therapies for inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 22:370-6. 2006
    ..The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance...
  87. doi request reprint Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit
    Liesbet Henckaerts
    Department of Medicine, Catholic University of Leuven, Leuven, Belgium
    Crit Care Med 37:192-201, e1-3. 2009
    ..Our aim was to study the influence of single nucleotide polymorphisms in selected genes involved in innate immunity on the development of bacteremia or risk of death in patients admitted to a medical intensive care unit...
  88. ncbi request reprint Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases
    Marie Joossens
    Department of Gastroenterology, University Hospital, Leuven, Belgium
    Inflamm Bowel Dis 13:580-4. 2007
    ..In this family the father developed Crohn's disease (CD) after moving from Morocco to Belgium and successively 4 of his 8 children subsequently developed CD. There was no previous history of familial CD...
  89. ncbi request reprint CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:272-7. 2006
    ..We therefore investigated the role of the functional 32-bp deletion in this gene (CCR5-Delta32) with regard to susceptibility to PSC...
  90. doi request reprint Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease
    Nathalie Vermeulen
    Department of Internal Medicine, University Hospital Leuven, Leuven, Belgium
    Clin Chem 54:534-41. 2008
    ..alpha-Enolase has been proposed as a target antigen in IBD. We evaluated the prevalence and diagnostic value of anti-alpha-enolase antibodies in IBD and related disorders...
  91. ncbi request reprint Clinical and genetic factors associated with sacroiliitis in Crohn's disease
    Harald Peeters
    Department of Gastroenterology, Ghent University Hospital, Gent, Belgium
    J Gastroenterol Hepatol 23:132-7. 2008
    ..Association of SI with CARD15 polymorphisms has recently been suggested. In a multicenter study, we investigated the association of SI in CD patients with clinical phenotypes, other EIM and CARD15 polymorphisms...
  92. ncbi request reprint Crohn's disease and month of birth
    Marc Van Ranst
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 11:597-9. 2005
    ..Some studies suggested an association between the month of birth and the later development of IBD. We studied this putative relationship in a large cohort of Belgian patients with Crohn's disease (CD)...
  93. doi request reprint Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
    Gert Van Assche
    Division of Gastroenterology and Laboratory for Pharmaceutical Biology, University of Leuven, Leuven, Belgium
    Gut 61:229-34. 2012
    ..A study was undertaken to evaluate prospectively the impact of elective switching of patients with Crohn's disease well controlled with intravenous infliximab to subcutaneous adalimumab in a controlled trial...
  94. ncbi request reprint Emerging biological treatments in inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Dig Dis 24:131-6. 2006
    ..As illustrated by unexpected but devastating brain infections with anti-adhesion molecules, clinicians should be aware that the powerful immunomodulatory capacity of biologicals necessitates a rigorous safety follow-up...